Skip to content
DefDex

Federal award

GRIFOLS DIAGNOSTIC SOLUTIONS INC.

N6264520P0006

Contract

Obligated and Ceiling

Obligated (net)
$2,181,820.00
Ceiling (potential value, not spending)
$2,181,820.00
Current value
$2,181,820.00
Gross positive obligations
$2,181,820.00

Obligated is what the government has committed, net of de-obligations. The ceiling is the most the award or vehicle could ever reach; it is shown separately and never added to, or compared as, spending.

Award Details

Recipient
GRIFOLS DIAGNOSTIC SOLUTIONS INC. · R4N2Y6E9D6H7
Owner company
Not a reviewed companyNo reviewed company owns this recipient.
Reported parent
GRIFOLS SA · KHDVUGFN8X53
Awarding agency
Department of War · sub-agency 97DH · office HT9410
Funding agency
Department of War · sub-agency 97DH
Product or service (PSC)
6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS
Industry (NAICS)
325413 · IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING
PIID
N6264520P0006
Award type code
B
Actions
15 · Jan 28, 2020 to Apr 11, 2024
Why it is listed
gross positive obligations of $100k or more (contracts)

Open this award on USAspending →

Action History15

Award actions
DateFYModAction typeObligationCompany in company totals
Apr 11, 2024FY2024P00014B$218,640.00
—
Dec 18, 2023FY2024P00013B$243,900.00
—
Jul 31, 2023FY2023P00012G$0.00
—
Feb 2, 2023FY2023P00011C$462,540.00
—
Sep 19, 2022FY2022P00010B$0.00
—
Sep 6, 2022FY2022P00009B$0.00
—
Jun 27, 2022FY2022P00008M$0.00
—
May 20, 2022FY2022P00007M$0.00
—
Jan 12, 2022FY2022P00006M$462,540.00
—
Nov 10, 2021FY2022P00005M$0.00
—
Sep 16, 2021FY2021P00004G$0.00
—
Apr 20, 2021FY2021P00003B$127,600.00
—
Jan 26, 2021FY2021P00002C$410,720.00
—
Sep 21, 2020FY2020P00001G$0.00
—
Jan 28, 2020FY20200—$255,880.00
—

Newest first. Every obligation is shown as reported, including zero and negative (de-obligation) actions. Award lists belong to the company of the latest action; company totals credit each action to the company named on that row, so a note marks rows where the two differ.